FDA approves Akeega (niraparib + abiraterone acetate with prednisone) for BRCA2-mutated metastatic castration-sensitive prostate cancer, showing significant improvements in radiographic progression-free survival and delayed symptomatic progression, with a safety profile consistent with the individual therapies.

FDA approves darolutamide (Nubeqa) for mCSPC: 46% reduction in disease progression risk vs placebo in ARANOTE trial.

PSA nadir <0.2 ng/mL within 9 months shows 54% lower death risk vs 22% for ≥90% decline in mCSPC veterans receiving ADT-based therapy.